Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 1, 2005, Pages 24-35

  Monte, Maria J ^a   Ballestero, Maria R ^b   Briz, Oscar ^a   Perez, Maria J ^b   Marin, Jose J G ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CASPASE 3; CISPLATIN; CISPLATIN DERIVATIVE; COPPER COTRANSPORTER 1; CYTOSTATIC AGENT; DIAMMINEBISURSODEOXYCHOLATE PLATINUM; DIAMMINECHLOROCHOLYLGLYCINATE PLATINUM; DNA FRAGMENT; GLYCOCHOLIC ACID; LACTATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN 2; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL STRAIN HEPG2; CELL TYPE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DNA ADDUCT; DNA DENATURATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; ILEUM; INTESTINE CELL; INTESTINE MUCOSA; INTESTINE TUMOR; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SMALL INTESTINE; UPREGULATION; WATER ABSORPTION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DNA ADDUCTS; DNA FRAGMENTATION; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MALE; MICE; NECROSIS; ORGANOPLATINUM COMPOUNDS; URSODEOXYCHOLIC ACID;

EID: 25644439976     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.086165     Document Type: Article

References (40)

1. Bai J, Rodriguez AM, Melendez JA, and Cederbaum AI (1999) Overexpression of catalase in cytosolic or mitochondrial compartment protects HepG2 cells against oxidative injury. J Biol Chem 274:26217-26224.
2. Bartoszek A, Sielenko A, and Wesiora M (2003) Versatile method employing basic techniques of genetic engineering to study the ability of low-molecular-weight compounds to bind covalently with DNA in cell-free systems. Anal Biochem 313:53-59.
3. Benz C, Angermuller S, Tox U, KlotersPlachky P, Riedel HD, Sauer P, Stremmel W, and Stiehl A (1998) Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes. J Hepatol 28:99-106.
4. Boulikas T and Vougiouka M (2003) Cisplatin and platinum drugs at the molecular level. Review. Oncol Rep 10:1663-1682.
5. Briz O, Macias RIR, Vallejo M, Silva A, Serrano MA, and Marin JJG (2003) Usefulness of liposome-encapsulated cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors. Mol Pharmacol 63:742-750.
6. Briz O, Serrano MA, Rebollo N, Hagenbuch B, Meier PJ, Koepsell H, and Marin JJG (2002) Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine chloro cholylglycinate platinum(II) and cis-diammine bisursodeoxycholate platinum(II) toward liver cells. Mol Pharmacol 61:853-860.
7. Canon JL, Humblet Y, and Symann M (1990) Resistance to cisplatin. How to deal with the problem? Eur J Cancer 26:1-3.
8. Criado JJ, Dominguez MF, Medarde M, Fernandez ER, Macias RIR, and Marin JJG (2000) Structural characterization, kinetic studies and in vitro biological activity of new cis-diamminebis-cholylglycinate (O,O′) Pt(II) and cis-diamminebisursodeoxycholate (O,O′) Pt(II) complexes. Bioconjug Chem 11:167-174.
9. Criado JJ, Macias RIR, Medarde M, Monte MJ, Serrano MA, and Marin JJG (1997) Synthesis and characterization of the new cytostatic complex cis-diammineplatinum (II)-chlorocholylglycinate. Bioconjug Chem 8:453-458.
10. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, and Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929-937.
11. Dominguez MF, Macias RIR, Izco-Basurko I, de la Fuente A, Pascual MJ, Criado JM, Monte MJ, Yajeya J, and Marin JJG (2001) Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. J Pharmacol Exp Ther 297:1106-1112.
12. Evers R, Zaman GJR, van Deemter L, Jansen H, Calafat J, Oomen LCJM, Oude Elferink RPJ, Borst P, and Schinkel AH (1996) Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Investig 97:1211-1218.
13. Gutmann I and Wahlefeld AW (1974) L-(+)-lactate. Determination with lactate dehydrogenase and NAD, in Methods of Enzymatic Analysis (Bergmeyer HU ed) pp 1464-1468, Academic Press Inc., New York.
14. Hasegawa JI, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda H, and Tsujimoto Y (1996) Involvement of CPP32/Yama (-like) proteases in Fas-mediated apoptosis. Cancer Res 56:1713-1718.
15. Horacek P and Drobnik J (1971) Interaction of cis- dichlorodiammineplatinum (II) with DNA. Biochim Biophys Acta 254:341-347.
16. Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, and Heber D (2003) Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 22:663-670.
17. Jarnagin WR, Ruo L, Little SA, Klimstra D, D'Angelica M, DeMatteo RP, Wagman R, Blumgart LH, and Fong Y (2003) Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98:1689-1700.
18. Larena MG, Martinez-Diez MC, Macias RIR, Dominguez MF, Serrano MA, and Marin JJG (2002) Relationship between tumor cell load and sensitivity to cytostatic effect of two novel platinum-bile acid complexes, Bamet-D3 and Bamet-UD2. J Drug Target 10:397-404.
19. Larena MG, Martinez-Diez MC, Monte MJ, Dominguez MF, Pascual MP, and Marin JJG (2001) Liver organotropism and biotransformation of a novel platinumursodeoxycholate derivative, Bamet-UD2, with enhanced antitumor activity. J Drug Target 9:185-200.
20. Leonard GD, Fojo T, and Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8:411-424.
21. Macias RIR, Monte MJ, El-Mir MY, Villanueva GR, and Marin JJG (1998) Transport and biotransformation of the new cytostatic complex cis-diammmineplatinum(II)-chlorocholylglycinate (Bamet-R2) by the rat liver. J Lipid Res 39:1792-1798.
22. Mancini R, Tedesco M, Garufi C, Filippini A, Arcieri S, Caterino M, Pizzi G, Cortesi E, Spila A, Sperduti I, et al. (2003) Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases. Anticancer Res 23:1837-1841.
23. Marin JJG, Macias RIR, Criado JJ, Bueno A, Monte MJ, and Serrano MA (1998) DNA interaction and cytostatic activity of the new liver organotropic complex of cisplatin with glycocholic acid: Bamet-R2. Int J Cancer 78:346-352.
24. Marin JJG, Macias RIR, Monte MJ, El-Mir MY, and Serrano MA (2001) Liver targeting of cisplatin-derived cytostatic drugs (Bamets) by coupling to bile acids, in Biology of Bile Acids in Health and Diseases (van Berge Henegouwen GP, Keppler D, Leuschner U, Paumgartner G, and Stiehl A eds) pp 271-277, Kluwer Academic Publishers, Dordrecht, The Netherlands.
25. Markwell MAK, Haas SM, Bieber LL, and Tolbert NE (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87:206-210.
26. Martinez-Diez MC, Larena MG, Serrano MA, Macias RIR, Izco-Basurko I, and Marin JJG (2000) Relationship between DNA-reactivity and cytostatic effect of two novel bile acid-platinum derivatives, Bamet UD2 and Bamet-D3. Anticancer Res 20:3315-3321.
27. Minemura M, Tanimura H, and Tabor E (1999) Overexpression of multidrug resis-tance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol 15:559-563.
28. Muggia FM (1991) Cisplatin update. Semin Oncol 18:1-4.
29. O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, and Ko CY (2003) Rates of colon and rectal cancers are increasing in young adults. Am Surg 69:866-872.
30. O'Dwyer PJ and Johnson SW (2003) Current status of oxaliplatin in colorectal cancer. Semin Oncol 30:78-87.
31. Ormerod MG, Orr RM, and Peacock JH (1994) The role of apoptosis in cell killing by cisplatin-a flow cytometric study. Br J Cancer 69:93-100.
32. Ostling O and Johanson KJ (1984) Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem Biophys Res Commun 123:291-298.
33. Paschke R, Kalbitz J, Paetz C, Luckner M, Mueller T, Schmoll H-J, Mueller H, Sorkau E, and Sinn E (2003) Cholic acid-carboplatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds. J Inorg Biochem 94:335-342.
34. Perez MJ, Macias RIR, Duran C, Monte MJ, Gonzalez-Buitrago JM, and Marin JJG (2005) Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. J Hepatol 43:324-332.
35. Pinto AL and Lippard SJ (1985) Binding of the antitumor drug cis-diamminedichloroplatinum (II) (cis-platin) to DNA. Biochim Biophys Acta 780:167-180.
36. Powolny A, Xu J, and Loo G (2001) Deoxycholate induces DNA damage and apoptosis in human colon epithelial cells expressing either mutant or wild-type p53. Int J Biochem Cell Biol 33:193-203.
37. Safaei R and Howell SB (2005) Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53:13-23.
38. Salvesen GS and Dixit VM (1997) Caspases: intracellular signaling by proteolysis. Cell 14:443-446.
39. MS, Amersi F, Golish SR, Ortiz JA, Zaky J, Finklestein D, Busuttil RW, and Imagawa DK (2003) Prevalence of metastases in hepatocellular carcinoma: risk factors and impact on survival. Am Surg 69:879-885.
40. Smit JW, Schinkel AH, Muller M, Weert B, and Meijer DKF (1998) Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology 27:1056-1063.